ABSTRACT

This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Bupropion. Continue bupropion pharmacotherapy for seven to twelve weeks while monitoring individual patient response. Bupropion is the first non-nicotine drug approved for the symptomatic management of nicotine withdrawal associated with tobacco smoking cessation. Bupropion does not inhibit monoamine oxidase and is only a relatively weak inhibitor of the neuronal re-uptake of norepinephrine and serotonin. Bupropion appears to decrease craving and other signs and symptoms of nicotine withdrawal by increasing dopamine and norepinephrine levels, two of the neurotransmitters that are stimulated by nicotine. Bupropion pharmacotherapy has been commonly associated with agitation, anorexia, constipation, dizziness, dry mouth, headache, insomnia, migraine, nausea, tremor, weight loss, and vomiting. Signs and symptoms of bupropion overdosage include fever, hallucinations, loss of consciousness, seizures, and tachycardia.